Advertisement

Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine’s Rapid Onset Antidepressant Actions in Rodent Models

  • Gerard Sanacora
    Correspondence
    Address correspondence to Gerard Sanacora, M.D., Ph.D., Department of Psychiatry, Yale University School of Medicine, 100 York Street, Suite 2J, New Haven, CT 06511.
    Affiliations
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
    Search for articles by this author
      SEE CORRESPONDING ARTICLE ON PAGE 65
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Trullas R.
        • Skolnick P.
        Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.
        Eur J Pharmacol. 1990; 185: 1-10
        • Berman R.M.
        • Cappiello A.
        • Anand A.
        • Oren D.A.
        • Heninger G.R.
        • Charney D.S.
        • et al.
        Antidepressant effects of ketamine in depressed patients.
        Biol Psychiatry. 2000; 47: 351-354
        • Zarate Jr., C.A.
        • Singh J.B.
        • Carlson P.J.
        • Brutsche N.E.
        • Ameli R.
        • Luckenbaugh D.A.
        • et al.
        A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
        Arch Gen Psychiatry. 2006; 63: 856-864
        • Sanacora G.
        • Frye M.A.
        • McDonald W.
        • Mathew S.J.
        • Turner M.S.
        • Schatzberg A.F.
        • et al.
        A consensus statement on the use of ketamine in the treatment of mood disorders.
        JAMA Psychiatry. 2017; 74: 399-405
        • Adaikkan C.
        • Taha E.
        • Barrera I.
        • David O.
        • Rosenblum K.
        Calcium/calmodulin-dependent protein kinase II and eukaryotic elongation factor 2 kinase pathways mediate the antidepressant action of ketamine.
        Biol Psychiatry. 2018; 84: 65-75
        • Li N.
        • Lee B.
        • Liu R.J.
        • Banasr M.
        • Dwyer J.M.
        • Iwata M.
        • et al.
        mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
        Science. 2010; 329: 959-964
        • Duman R.S.
        • Aghajanian G.K.
        Neurobiology of rapid acting antidepressants: Role of BDNF and GSK-3beta.
        Neuropsychopharmacology. 2014; 39: 233
        • Autry A.E.
        • Adachi M.
        • Nosyreva E.
        • Na E.S.
        • Los M.F.
        • Cheng P.F.
        • et al.
        NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
        Nature. 2011; 475: 91-95
        • Browne C.A.
        • Lucki I.
        Antidepressant effects of ketamine: Mechanisms underlying fast-acting novel antidepressants.
        Front Pharmacol. 2013; 4: 161
        • Reardon S.
        Sex matters in experiments on party drug—in mice.
        Nature. 2017; (Available at:)

      Linked Article